Cargando…

Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer

Purpose: Radical surgery is the preferred method for local high-risk and limited progressive prostate cancer in the routine clinical setting. However, current guidelines do not recommend neoadjuvant hormone therapy (NHT). Opinions regarding NHT vary among individual clinicians. According to the expe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Bing-Lei, Yao, Lin, Fan, Yu, Wang, Yu, Meng, Yi-Sen, Zhang, Qian, He, Zhi-Song, Jin, Jie, Zhou, Li-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522651/ https://www.ncbi.nlm.nih.gov/pubmed/31190986 http://dx.doi.org/10.2147/CMAR.S196378

Ejemplares similares

Role of Neoadjuvant Chemotherapy in Locally Advanced Carcinoma Stomach: An Analysis of the Short-Term Outcomes
por: Sivacoumarane, Sooryabhala, et al.
Publicado: (2022)

Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma
por: Jung, Jang Han, et al.
Publicado: (2017)

Neoadjuvant Hormonal Therapy Preceding Radical Prostatectomy for Clinically Localized Prostate Cancer: Early Postoperative Complications and Biochemical Recurrence
por: Yang, Seung Woo, et al.
Publicado: (2011)

Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
por: Pinkawa, Michael, et al.
Publicado: (2012)

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
por: Mellado, B, et al.
Publicado: (2009)

Impact of Cerebrovascular Disease on Survival Benefits from Local Treatment in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
por: Kim, Tae Jin, et al.
Publicado: (2019)

Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis
por: Liu, Wen, et al.
Publicado: (2021)

Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer
por: Yang, Jianguo, et al.
Publicado: (2023)

Analysis of short-term efficacy as defined by RECIST and pathological response of neoadjuvant chemotherapy comprised paclitaxel and cisplatin followed by radical surgery in patients with locally advanced cervical cancer: A prospective observational study
por: He, Yue, et al.
Publicado: (2018)

Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer
por: Liu, Jianyu, et al.
Publicado: (2022)

Open vs. laparoscopic surgery for locally advanced gastric cancer after neoadjuvant therapy: Short-term and long-term survival outcomes
por: Wang, Nianchang, et al.
Publicado: (2020)

Long-term cancer-related fatigue outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with hormonal therapy
por: Luo, Hua-Chun, et al.
Publicado: (2016)

Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer
por: Sankaran, Sindhu, et al.
Publicado: (2023)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Schneider, Jean, et al.
Publicado: (2020)

Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching
por: Kim, Sung Han, et al.
Publicado: (2018)

Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer
por: Milecki, Piotr, et al.
Publicado: (2009)

Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

How to Measure “Short-Term Hormonal Effects”?
por: Heinemann, Lothar A. J.
Publicado: (2009)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

On the Use of High‐Resolution and Deep‐Learning Seismic Catalogs for Short‐Term Earthquake Forecasts: Potential Benefits and Current Limitations
por: Mancini, S., et al.
Publicado: (2022)

Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
por: Gogia, Ajay, et al.
Publicado: (2018)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
por: Zhu, Yinjie, et al.
Publicado: (2023)

Progress in neoadjuvant therapy for gastric cancer
por: Su, Peng-Fei, et al.
Publicado: (2022)

Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry
por: Huber, Thomas, et al.
Publicado: (2017)

Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer
por: Hou, Sicong, et al.
Publicado: (2021)

Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer
por: Hou, Cheng-Pang, et al.
Publicado: (2014)

Vaccination: short- to long-term benefits from investment
por: Carroll, Stuart, et al.
Publicado: (2015)

Benefit finding in long-term prostate cancer survivors
por: Lassmann, Irène, et al.
Publicado: (2021)

Short-Term Clinical and Oncological Outcome of Prolonging Operation Interval After Neoadjuvant Chemoradiotherapy for Locally Advanced Middle and Low Rectal Cancer
por: Yang, Jianguo, et al.
Publicado: (2020)

Short-Term Clinical Efficacy of Neoadjuvant Chemotherapy Combined With Laparoscopic Gastrectomy for Locally Advanced Siewert Type II and III Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Propensity Score-Matched Study
por: Feng, Qing, et al.
Publicado: (2021)

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer
por: Miki, Kenta, et al.
Publicado: (2016)

Clinical Analysis of Perioperative Outcomes on Neoadjuvant Hormone Therapy before Laparoscopic and Robot-Assisted Surgery for Localized High-Risk Prostate Cancer in a Chinese Cohort
por: Sun, Guangyu, et al.
Publicado: (2022)

Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: D’Alimonte, Lucrezia, et al.
Publicado: (2020)

Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
por: Heinrich, Stefan, et al.
Publicado: (2017)

Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese
por: Wang, Cheng-Zhi, et al.
Publicado: (2016)

Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis
por: Des Guetz, Gaëtan, et al.
Publicado: (2021)

Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies
por: Zhou, Yuedan, et al.
Publicado: (2022)

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_19d44khjjofvihibtd0aveb3gs